Genetic products company,
) entered into a major contract with UK Biobank, a long-term
epidemiological study investigating complex human diseases
affecting public health. The Axiom Genotyping Solution from
Affymetrix will be used to generate superior-quality genotypes,
which in turn will provide researchers with valuable data to
study genetic factors in human diseases.
The UK BioBank has collected 500,000 DNA samples from UK
residents between the age of 40 and 69 from 2006 till 2010. The
aim of this large scale project is to improve the diagnosis and
treatment of diseases such as cancer, heart diseases, stroke,
diabetes, arthritis, osteoporosis, eye disorders, depression and
forms of dementia.
The alliance with UK Biobank is in accordance with Affymetrix's
long-term strategy to expand its reach into the translational
medicine market. The Axiom Genotyping Solution from Affymetrix is
perfectly suitable for such large scale genotyping studies. Its
flexibility and ability to produce a large amount of data in a
cost effective manner has provided the solution with a
However, management does not expect any material gain from the
contract in 2013 as it will start providing data at the end of
the year. The major portion of revenues is expected to be
generated in 2014.
Earlier in Nov 2012, the company had entered into a research and
service partnership with South Africa-based Centre for Proteomic
and Genomic Research (CPGR) organization. The CPGR organization
provided Affymetrix's GeneTitan Multi-Channel (MC) Instrument
along with customizable Axiom Genotyping Arrays to the African
research community in order to advance high-throughput genomics
research and personalized medicine studies in Africa.
Affymetrix is a leading provider of microarray-based products and
services to the global research community. Along with
), it is one of the two major providers of microarray
technologies, primarily used in the field of genetic research.
Affymetrix holds a leading position in the gene expression
products and services market.
However, research and development spending by Affymetrix's
customers have fallen considerably due to a weak macroeconomic
environment coupled with stringent government actions such as
The company currently carries a Zacks Rank #3 (Hold). Companies
), both carrying a Zacks Rank #1 (Strong Buy), are expected to do
well in the Medical-Biomed/Gene industry.
AFFYMETRIX INC (AFFX): Free Stock Analysis
CLEVELAND BIOLB (CBLI): Free Stock Analysis
CYTOKINETCS INC (CYTK): Free Stock Analysis
ILLUMINA INC (ILMN): Free Stock Analysis
To read this article on Zacks.com click here.